GlassScriptPhysician profile
Patricia A Bacon
NPI 1033291026
$3,699.04
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $646 · 2021: $1,014 · 2022: $1,000.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $550.14 | 2019-2022 | |
| Novo Nordisk INC | $399.54 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.31 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $308.46 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $288.00 | 2019-2022 | |
| Lilly USA, LLC | $214.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $201.57 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $183.84 | 2019-2022 | |
| Abbott Laboratories | $179.37 | 2020-2022 | |
| Glaxosmithkline, LLC. | $152.65 | 2019-2021 | |
| Pfizer INC. | $145.52 | 2019-2022 | |
| Amgen INC. | $138.32 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.86 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $75.38 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $72.51 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $68.62 | 2022 | |
| Eisai INC. | $37.07 | 2021 | |
| Astellas Pharma US INC | $31.66 | 2019 | |
| Medtronic Minimed, INC. | $30.76 | 2020 | |
| Novartis Pharmaceuticals Corporation | $30.12 | 2020-2022 | |
| Zealand Pharma US, INC. | $26.82 | 2022 | |
| Esperion Therapeutics, INC. | $21.76 | 2021 | |
| Amarin Pharma, INC. | $20.94 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.74 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.87 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.50 | 2022 | |
| Dermira, INC. | $13.24 | 2020 | |
| Endo Pharmaceuticals INC. | $13.01 | 2021 | |
| Allergan, INC. | $11.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Bacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.